Experimental medication has proven to be sure and effective in treating children with MIS-C

In a small test. Consequently, the researchers of the mass general Brigham found a medication designed to treat celiac disease supported a faster return to normal activities for patients following COVVID.

Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition that can occur after a COVVI-19 infection. However, with high fevers, gastrointestinal symptoms and potentially fatal cardiac lesions. Similarly, A small randomized clinical trial led by Mass Brigham General Researchers revealed that the Oral Larazotide medication-an experimental medication originally designed to treat celiac disease was safe. Moreover, effective in the treatment of children with MIS-C. For example, Their results are published in Translational scientific medicine.

Although our study is low. Similarly, its results are powerful and have implications not only for MIS-C, but potentially for a long experimental medication proven sure effective cocvid. Furthermore, Our results suggest that the Larazotide is safe and quickly solves the symptoms in children with MIS-C. We now run a clinical trial to test if Larazotide can also be useful therapy for treating patients with. long covid. “”

Lael Yonker, MD, principal author, co -director of the cystic fibrosis center, the therapeutic development center for cystic fibrosis and the pulmonary genetic clinic with Brigham mass for children

Current MIS treatments are limited. Some patients receive general anti-inflammatory drugs, but many experience a rebound in symptoms after taking a course. These drugs are not designed to target the sticking SARS-COV-2 viral particles which can persist in the intestine. Enter the Larazotide, a medication administered orally which makes target the intestine. Larazotide strengthens intestinal barriers to limit the number of Sars-Cov-2 viral particles of the materials type. which leave the intestines and enter traffic.

experimental medication proven sure effective

To test the efficiency. safety of the Larazotide as a Miss treatment, the researchers led a clinical trial in double blind with 12 children suffering from an early stage. The study was partly funded by the National Institutes of Health. Each patient has randomly received a placebo. a larazotide four times a day for 21 days, then was followed over six months of recovery. Children who received Larazotide showed a faster resolution of gastrointestinal symptoms. faster clearance of SARS-COV-2 viral particles and faster return to normal activities. The results show that Larazotide can be a safe and promising treatment option for children with MIS-C.